Trial Profile

A pivotal confirmatory trial of INO-3107 in adult patients with Recurrent Respiratory Papillomatosis (RRP)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INO 3107 (Primary)
Indications Recurrent respiratory papillomatosis
Focus Registrational; Therapeutic Use
Sponsors Inovio Pharmaceuticals

Most Recent Events

09 Jan 2025 According to a Inovio Pharmaceuticals media release, company believes that the design of the confirmatory trial could also support expansion into global markets based on feedback received to date from European and UK regulators.
09 Jan 2025 According to a Inovio Pharmaceuticals media release, company anticipate to initiate this confirmatory trial in 2025.
10 Oct 2023 According to a Inovio Pharmaceuticals media release, data from this study no longer required to support Biological License Application (BLA) submission.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com